Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer

Abstract Lung cancer remains one of the most common malignancies, and its brain metastases significantly worsen the prognosis for patients. Current treatments for lung cancer face many challenges, including poor drug accumulation and the inability to simultaneously control primary and metastatic tum...

Full description

Saved in:
Bibliographic Details
Main Authors: Xianglei Fu, Yanbin Shi, Hang Wu, Yankun Zhang, Yingying Liu, Xiaoyu Wan, Xiangqin Chen, Jiamin Zhou, Shengnan Qiu, Xiaogang Zhao, Zhongxian Tian, Lian Li, Hengchang Zang, Guimei Lin
Format: Article
Language:English
Published: Nature Portfolio 2025-04-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-025-58312-5
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849726233443565568
author Xianglei Fu
Yanbin Shi
Hang Wu
Yankun Zhang
Yingying Liu
Xiaoyu Wan
Xiangqin Chen
Jiamin Zhou
Shengnan Qiu
Xiaogang Zhao
Zhongxian Tian
Lian Li
Hengchang Zang
Guimei Lin
author_facet Xianglei Fu
Yanbin Shi
Hang Wu
Yankun Zhang
Yingying Liu
Xiaoyu Wan
Xiangqin Chen
Jiamin Zhou
Shengnan Qiu
Xiaogang Zhao
Zhongxian Tian
Lian Li
Hengchang Zang
Guimei Lin
author_sort Xianglei Fu
collection DOAJ
description Abstract Lung cancer remains one of the most common malignancies, and its brain metastases significantly worsen the prognosis for patients. Current treatments for lung cancer face many challenges, including poor drug accumulation and the inability to simultaneously control primary and metastatic tumors. Here, we show that the mRNA-binding protein insulin-like growth factor 3 is crucial for non-small cell lung cancer progression and metastasis. We construct an inhalable nanoliposome system to co-deliver osimertinib and DNA plasmid for gene knockdown. Upon inhalation, these nanoparticles efficiently penetrate pulmonary barriers and accumulate in lungs by mimicking natural lung surfactants. Within tumor cells, released osimertinib inhibits tumor growth, while the DNA triggers the production of engineered exosomes that can travel to the brain to suppress tumors. This strategy effectively inhibits both primary and metastatic tumors while enhancing antitumor immune responses. This work suggests that this inhalable nanomedicine offers a safe and versatile strategy for cancer therapy.
format Article
id doaj-art-1c1e477c92534524842fd2dbbfdbd7e9
institution DOAJ
issn 2041-1723
language English
publishDate 2025-04-01
publisher Nature Portfolio
record_format Article
series Nature Communications
spelling doaj-art-1c1e477c92534524842fd2dbbfdbd7e92025-08-20T03:10:14ZengNature PortfolioNature Communications2041-17232025-04-0116111910.1038/s41467-025-58312-5Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancerXianglei Fu0Yanbin Shi1Hang Wu2Yankun Zhang3Yingying Liu4Xiaoyu Wan5Xiangqin Chen6Jiamin Zhou7Shengnan Qiu8Xiaogang Zhao9Zhongxian Tian10Lian Li11Hengchang Zang12Guimei Lin13NMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversitySchool of Mechanical and Automotive Engineering, Qilu University of Technology (Shandong Academy of Sciences)Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union Medical CollegeNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityDepartment of Thoracic Surgery, The Second Hospital of Shandong UniversityDepartment of Thoracic Surgery, The Second Hospital of Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityNMPA Key Laboratory for Technology Research and Evaluation of Drug Products, School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong UniversityAbstract Lung cancer remains one of the most common malignancies, and its brain metastases significantly worsen the prognosis for patients. Current treatments for lung cancer face many challenges, including poor drug accumulation and the inability to simultaneously control primary and metastatic tumors. Here, we show that the mRNA-binding protein insulin-like growth factor 3 is crucial for non-small cell lung cancer progression and metastasis. We construct an inhalable nanoliposome system to co-deliver osimertinib and DNA plasmid for gene knockdown. Upon inhalation, these nanoparticles efficiently penetrate pulmonary barriers and accumulate in lungs by mimicking natural lung surfactants. Within tumor cells, released osimertinib inhibits tumor growth, while the DNA triggers the production of engineered exosomes that can travel to the brain to suppress tumors. This strategy effectively inhibits both primary and metastatic tumors while enhancing antitumor immune responses. This work suggests that this inhalable nanomedicine offers a safe and versatile strategy for cancer therapy.https://doi.org/10.1038/s41467-025-58312-5
spellingShingle Xianglei Fu
Yanbin Shi
Hang Wu
Yankun Zhang
Yingying Liu
Xiaoyu Wan
Xiangqin Chen
Jiamin Zhou
Shengnan Qiu
Xiaogang Zhao
Zhongxian Tian
Lian Li
Hengchang Zang
Guimei Lin
Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
Nature Communications
title Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
title_full Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
title_fullStr Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
title_full_unstemmed Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
title_short Inhalable liposomal delivery of osimertinib and DNA for treating primary and metastasis lung cancer
title_sort inhalable liposomal delivery of osimertinib and dna for treating primary and metastasis lung cancer
url https://doi.org/10.1038/s41467-025-58312-5
work_keys_str_mv AT xiangleifu inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT yanbinshi inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT hangwu inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT yankunzhang inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT yingyingliu inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT xiaoyuwan inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT xiangqinchen inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT jiaminzhou inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT shengnanqiu inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT xiaogangzhao inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT zhongxiantian inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT lianli inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT hengchangzang inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer
AT guimeilin inhalableliposomaldeliveryofosimertinibanddnafortreatingprimaryandmetastasislungcancer